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Abstract
Introduction. Global public health is challenged by two concurrent epidemics; COVID-19
and obesity. Considering the global prevalence of obesity, exploring relationships with
COVID-19 are of clinical importance. The aim was to provide a comprehensive summary
and recommendations on this relationship between COVID-19 and obesity.
Method. A literature search was performed to prepare a narrative review of COVID-19 and
obesity.
Results. An obesity state promotes chronic inflammation, vitamin D deficiency, hinders
immunity and causes mechanical lung compression. These increase susceptibilities to
COVID-19 infection, complications including the requirement of invasive ventilation.
Existing co-morbidities enhances these complications. Preventive measures of social
distancing and self-isolation may increase stigmatisation and psychological deterrents.
Hence, special recommendations targeting this vulnerable population are required.
Conclusion. The obese population is a COVID-19 vulnerable group, requiring special
attention during this pandemic to avoid complications and healthcare systems burden.
Lacking COVID-19 vaccination, regular physical activity and a healthy diet are recommended
with attention to mental health. A prolonged quarantine duration and administration of
prophylactic vitamin D may be considered.
Introduction
The global public health body is being challenged by two concurrent epidemics, SARS-CoV2,
also known as COVID-19 and obesity. SARS-CoV2 is an influenza-like virus that has affected
millions of people across the globe [1]. A link between influenza and obesity was reported
during the 2009 Influenza A virus H1N1 pandemic. At the time, individuals with obesity
had an increased risk of getting a severe disease as well as increase in hospitalisation and
mortality rates [2]. Similarly, an association has been identified between overweight and
obese status and severity of COVID-19 infection [3]. Unfortunately, a large proportion of
the world’s population has been reported to be either overweight or obese, hence increasing
the risk of acquiring a severe COVID-19 infection [4]. This indirectly will increase the burden
on the healthcare systems with a possibility of collapse [5]. Therefore, it is considered timely to
explore the relationship between COVID-19 and obesity and their clinical importance. In this
review, we aimed to provide a comprehensive summary of the literature and recommendations
on the relationship between COVID-19 and obesity.
Method
A literature search using ‘COVID-19’, ‘Obesity’ and ‘Abdominal Obesity’ as the keywords was
performed through PubMed and Google search engines. Published articles pertaining to the
aim of this review were considered. Furthermore, the search was extended to international
organisations websites in order to establish recommendations and information published by
these entities for the population with obesity. The international organisations included
were: World Health Organization (WHO), Centres for Disease Control and Prevention
(CDC), World Obesity and European Association for the Study of Obesity.
Obesity, inflammatory, thrombotic responses and COVID-19
Obesity is defined as a body mass index (BMI) higher than 30 Kg/m2 [6]. Those individuals
with severe obesity, defined as BMI of 40 Kg/m2 or higher have been labelled as ‘vulnerable’
by the ‘Centres for Disease Control and Prevention’ (CDC) [7]. While the WHO together with
the World Obesity Federation have declared that both overweight and obesity are potential risk
factors for worse COVID-19 outcomes [8,9]. In fact, it has been reported that the majority of
COVID-19 patients admitted to the intensive care unit (ICU) were obese [10].
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The obesity phenotype consists of the accumulation of adipose
tissue, which is responsible for the development of localised
inflammation and promotion of chronic systemic low-grade
inflammation [11]. The pro-inflammatory markers C-reactive
protein and interleukin-6 are elevated as a response to the excess
adipose mass. Similarly, the pro-inflammatory product tumour
necrosis factor and the anti-fibrinolytic adipokine levels are also
increased. On the other hand, the anti-inflammatory adipokine,
adiponectin, is suppressed. Hence, in the presence of obesity,
there is a metabolic dysfunction resulting from an imbalance in
the expression of pro- and anti-inflammatory adipokines [12].
Subsequent to the suppression of adiponectin, macrophages
modulation is affected [12]. Macrophages infiltrate the adipose
tissue leading to inflammation, hypoxia, augmentation of chemo-
kine and adipocyte cell death. The adaptive immune system is
activated with the accumulation of macrophages within the
inflamed adipose tissue. CD8 + effector T cells are responsible
for a phenotypic switch of the macrophages to the proinflamma-
tory M1 macrophage phenotype, which has a role in the develop-
ment of insulin resistance. There is also an accumulation of NK
cells that are described as innate-like T lymphocytes which have
a role in adipose tissue inflammation and glucose intolerance
[13]. This chronic low-grade inflammatory response leads to the
impairment of the immune response and chemotaxis with a sub-
sequent disturbance of the immune surveillance system [14].
Local respiratory inflammatory responses also occur through
the increase in mast cells causing susceptibility to airway disease
[15]. Severe forms of COVID-19 are characterised by acute sys-
temic inflammation responses with high circulatory levels of
proinflammatory cytokines levels that lead to multiorgan failure
[16]. Hence, in light of the obesity pathophysiological low-grade
systemic inflammation and the cytokine storm caused by severe
forms of COVID-19, an obese individual acquiring COVID-19
is at a very high risk of an escalated systemic inflammation with
potentially fatal outcomes. This systemic inflammation can have
a deterrent effect on the blood flow within arteries precipitating
plaque rupture and resulting in pulmonary embolus, stroke or
myocardial infarction. In fact, in a Dutch study, it was reported
that 31% of the ICU COVID-19 admissions had venous or arterial
thrombotic complications [17].
COVID-19 infection has also been found to be linked with
coagulation disturbances and thrombotic mechanisms. It was
reported that complement-mediated microvascular injury was
identified in both the skin and lung post-mortem. Deposits of
C5b-9, C4d and MASP2 within the microvasculature of these
two systems indicated the activation of both the lectin-based
and alternative pathways [18]. Furthermore, elevated D-dimer
and fibrin degradation product levels were established in patients
with COVID-19 pneumonia [19,20]. Therefore, considering that
both COVID-19 infection and obesity pathophysiology are asso-
ciated with coagulation disturbances, individuals with obesity
are at higher risk of thrombotic events in the eventuality of a
COVID-19 infection.
Obesity, COVID-19 and pulmonary disease
The increase in abdominal circumference in obesity compresses
the lung structure while putting tethering forces between the
lung parenchyma and the airway. Reduced oxygen saturation at
the lung bases with impaired ventilation has been associated
with abdominal obesity [15]. The respiratory system has
angiotensin-converting enzyme 2 (ACE2) receptors which are
responsible for anti-inflammatory responses. The enveloped
spike glycoprotein of the SARS-CoV-2 enters human cells, includ-
ing the pulmonary system, through ACE2 [21]. It was postulated
that in severe COVID-19 infections there may be an imbalance in
the ACE2 activation pathways with an increase in the
pro-inflammatory response [22]. The SARS-CoV-2 interaction
with the renin-angiotensin-aldosterone system may lead to a
severe hypokalaemic state with increased susceptibility to tachyar-
rhythmias. Furthermore, hypokalaemia increases the vascular
permeability with a potential risk of respiratory distress syn-
drome. Therefore, COVID-19 infected obese individuals are at
an additional risk of an exaggerated systemic inflammatory and
electrolyte imbalance that may have a potentially fatal outcome.
Published reports from the COVID-19 pandemic experiences
state that a substantial proportion of individuals with obesity
required hospitalisation due to COVID-19 with a high mortality
rate [23,24]. It appears that obese patients younger than 60
years are mostly susceptible to such admissions [25].
Furthermore, individuals with obesity experienced a worse
COVID-19 respiratory outcome requiring ICU admissions for
invasive ventilation [26]. This increase in intensive care brings
forward other hardships due to potential increased difficulty in
intubation, central intravenous access, as well as most ICUs’
beds, are not designed to accommodate a high body weight
[27]. Moreover, due to weight and girth limits associated with
CT-scans and MRIs, which are the main diagnostic imaging
modalities used for infections including COVID-19, a proportion
of the obese population would be hindered from undergoing such
investigations [27]. These factors may hinder the essential care
required by this vulnerable population during the pandemic.
If the H1N1 influenza is considered, it was reported that an
increase in interleukin-8 is released in obese individuals when
compared to lean individuals [28]. Furthermore, on investigating
the effect of the influenza vaccine on obesity, it was found that the
CD8 + T-cell responses were defective when compared to the
healthy weight population while the levels of influenza vaccine
antibody declined. This increases the risk of acquiring a severe
influenza disease in the obese population due to the inability to
mount an immune response [29]. Therefore, considering the
already weakened immune response of the obese population,
the presence of localised pulmonary inflammation and the
obese response to the H1N1 influenza virus, it is expected that
a deterrent effect would be present if COVID-19 infection is
acquired. Furthermore, the delayed innate and adaptive immune
responses in the obese allow for an increase in viral replication,
spread and prolonged infections [30]. Additionally, the loss of
leptin receptors leads to an impaired viral clearance possibly aris-
ing from immune cell-mediated interactions within the respira-
tory epithelium [31]. Hence, it may be postulated that a similar
viral effect can occur in a COVID-19 infected obese individual.
Obesity and other co-morbidities
It is a well-known fact that an individual with obesity may have
other underlying co-morbidities such as type 2 diabetes and car-
diovascular disease [32–34]. Individuals with either disease have
also been declared as being vulnerable to COVID-19 infection
[35]. The presence of multiple concurrent chronic diseases contri-
butes to multimorbidity, a state that has been linked to higher
COVID-19 infection risk, worse health outcomes and increased
mortality [36]. This comes about from the ability of
SARS-CoV-2, as already stated, to access the host cells via the
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ACE2. The ACE2 is not only found in the lungs but is also
expressed by endothelial cells [37]. Therefore, COVID-19 can
affect a number of different organs.
An impaired cell-mediated immune response forms part of the
type 2 diabetes pathophysiology, putting these individuals at
higher risk of acquiring infections [38,39]. If infected by
COVID-19, the virus enters through the ACE2 receptor found
within pancreatic beta cells [21]. An acute onset of hypergly-
caemia occurs due to beta-cell dysfunction [40]. Therefore, indi-
viduals with obesity and type 2 diabetes are at a higher risk of
complications if infected by COVID-19. This may explain the
higher rates of ICU admissions by those who are obese.
It is not uncommon that individuals with obesity also have
underlying cardiovascular co-morbidities. Cardiovascular compli-
cations have been reported in COVID-19 infected individuals
through various modes. Direct myocardial injury can occur
through a similar pathway as in diabetes, where the
SARS-CoV-2 enters the myocardial cells through ACE2. The
ACE2 has a role in the neurohumoral regulation of the cardiovas-
cular system. Binding of the coronavirus leads to an alteration in
the ACE2 signalling pathways resulting in acute myocardial injury
[41]. The overall incidence of a COVID-19 acute myocardial
injury has been reported to vary between 8% and 12% [42,43].
Furthermore, in the presence of a systemic infection, there is a
higher cardiometabolic demand along with hypoxia arising
from acute respiratory distress that will impair the myocardial
oxygen demand–supply relationship leading to an acute myocar-
dial injury [44]. It has been reported that a substantial proportion
of COVID-19 patients requiring hospitalisation had cardio-
cerebrovascular disease and hypertension with an associated
three-fold and two-fold increased risk of ICU admissions [42].
Obesity, vitamin D and COVID-19
Vitamin D has an effect on the modulation of both the innate and
the adaptive immune responses [45]. A deficiency of this fat-
soluble vitamin D in individuals with obesity has been extensively
reported [46–48]. This may result from multifactorial factors
including insufficient exposure to solar radiation [49], inadequate
intake of vitamin D rich food [50], decrease in liver production of
25-hydroxy vitamin D due to liver steatosis [51] and reduction in
the bioavailability of this vitamin [52]. It is not uncommon that
obese individuals have hyperparathyroidism, that also causes sec-
ondary vitamin D deficiency [53]. Hence, integrating the patho-
physiology of obesity with an altered immune response and the
fact that these same individuals can also be vitamin D deficient,
the susceptibility to infection, including COVID-19 is enhanced.
Recent communications have suggested that vitamin D deficiency
enhances COVID-19 infection susceptibility while it was also sug-
gested that vitamin D should be given as a prophylaxis to all
acutely ill patients with COVID-19 [54,55]. Further research is
recommended to explore the relationship between vitamin D
and COVID-19.
Obesity and stigma
Stigma towards individuals with an obese bodily shape is com-
mon. This causes numerous negative consequences effecting
their mental and physical health [56]. The preventive measures
imposed by governments to contain the COVID-19 spread may
have a psychological toll on individuals with obesity. In indivi-
duals who are already stigmatised and experiencing higher rates
of depression, the social distancing and self-isolation measures
might tip the balance [27].
There is a higher chance that these individuals will consume
processed and tinned food rather than fresh food, to avoid
going out to the supermarket. The COVID-19 lock-down and
self-isolation may further enhance such habits. Another factor is
the actual physical space available to exercise at home.
Considering that gyms and other exercise facilities have been
asked to shut down as part of the COVID-19 containment mea-
sures, a true problem of physical inactivity is further com-
pounded. Hence, it is important that a media campaign using
different modes of delivery targeting this vulnerable group is set
up to promote a healthy choice of food as well as to engage in
physical activity that can be easily done at home. A number of
entities have set up physical activity workouts over social media
to engage all the population to be physically fit. One can also
observe that some TV stations are hosting a daily physical activity
regimen for those watching. Other initiatives have been set up
including various helplines even targeted to aid the mental health
during the COVID-19 pandemic [57].
Recommendations for obesity
A safe and effective COVID-19 vaccine is still being worked on by
the pharmaceutical companies, hence it is paramount that other
measures are instituted to protect the population especially the
vulnerable groups. Protecting the vulnerable forms one of the
seven principles for COVID-19 ethics along with population
health maximisation and solidarity [58]. The WHO and the
World Obesity Federation have issued a number of recommenda-
tions targeted at governments to ensure that national strategies are
set up to safeguard the short- and long-term health of the popu-
lation [8]. Although the containment measures of social distan-
cing, staying at home and banning of public gatherings are
paramount during this pandemic, it is essential that governments,
clinicians and individuals alike, acknowledge the impact these
measures will have on the population’s health. Lockdowns and
fear of contracting the virus can lead to reliance on high fat,
sugar and salted processed long-life foods with a reduction in
consumption of fresh fruit, vegetables and unprocessed meat.
This dietary change increases the risk of weight gain, especially
in the absence of physical activity opportunities when staying at
home. Such a scenario will have a deterrent effect on those already
struggling with overweight or obesity. Additionally, there is a risk
of previously normal-weight individuals to progress to an over-
weight or obese status during this pandemic. In fact, this issue
is a major concern for the World Obesity Federation and the
WHO [8,9]. This further enhances the potential presence of
food insecurity that the vulnerable population might experience
due to reduced access to shops and food assistance programmes
[8]. It was recommended that governments should ensure
adequate availability of nutritious food supply especially to
those with pre-existing health conditions as well as the vulnerable
groups. The provision of nutritious food is only one side of the
coin. Physical activity is another very important requisite for
healthy living. With the implementation of the government’s pre-
ventive measurements, opportunities for physical activity have
been restricted to the home. Even on easing of some restrictions,
most recreational places remained closed to avoid mass gather-
ings. Of note, physical activity has a dual effect of weight loss
and immune-modulatory actions. Undergoing regular physical
activity enhances cytokines production mediated through the toll-
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like receptors signalling pathways that improve host resistance
towards pathogen invasion [59]. Furthermore, physical activity
enhances the antioxidant defence system as well as the oxidative
stress reduction [60]. Hence, encouraging physical activity should
be on every government’s agenda.
Recommendations were put forward for the implementation of
policies that allow individuals to undergo physical activity in open
spaces while maintaining the required social distancing [8]. Social
and other types of media are good tools to disseminate the appro-
priate advocacy on the importance of the physical activity to the
nation [8]. A number of different organisations and sports entities
have set up online videos with different physical activity routines
that are easily done at home. Some countries have also engaged
national television stations in broadcasting daily exercise routines
for their viewers to follow. Obviously, it must be advised that such
exercise programmes should be tailored to the individual’s cap-
acity to exercise. The media has a critical role in disseminating
clear and transparent guidance on COVID-19 as well as providing
information about helplines for vulnerable groups among others.
It is important to note that during this difficult time, individuals
are more psychologically vulnerable, and this may impinge on their
mental health. Isolation, lack of social engagement, changes in the
daily routine and reduced physical activity are all triggers that may
impact on mental health. Vulnerable groups including the obese
population are more at risk of such mental health impact. This
may be coupled up with the potential distress arising from the
compromised treatment access that people living with obesity
may be facing, such as cancellations of follow-up consultations
with physicians and reductions in bariatric surgery during this
pandemic. Hence, it was recommended that governments recog-
nise the mental health impact that COVID-19 has on the popula-
tion and provide supporting services through virtual means as well
as helplines [8]. Furthermore, COVID-19 response strategies tar-
geting the non-communicable disease population including obesity
have been recommended. These should ensure adequate preven-
tion, management, support and advice to the vulnerable popula-
tion and their caregivers [9]. During this pandemic, a number of
physicians have shifted their practice to telemedicine in order to
continuously support their patients while abiding by social distan-
cing. Vulnerable groups including those living with obesity should
be encouraged to use such virtual means, both for management
and for psychological help. Here, again the media should play an
important role in disseminating information about such services.
Epidemiological data have established that the incubation period
of COVID-19 can last up to 14 days. However, in the previous influ-
enza pandemic, obese individuals were found to have a prolonged
shedding period [61]. Considering such evidence, international
organisations may consider recommending a prolonged quarantine
(presumably doubled) for people living with obesity with respect to
lean individuals. Furthermore, considering the established
COVID-19 pathophysiological coagulopathy risk, prophylactic
anti-coagulants may be recommended for those with obesity requir-
ing hospitalisation. Equally, regular electrolyte balance monitoring is
required during the hospitalisation duration. Nonetheless, Vitamin
D prophylaxis should be considered as being implemented as a rec-
ommendation for people living with obesity especially following the
containment strategies to stay at home.
Conclusion
Individuals with obesity are part of the vulnerable groups for
COVID-19. Mechanical respiratory restriction and metabolic
inflammatory responses resulting from the increased adiposity
hinders the respiratory system. Hindrance of both innate and
adoptive immune response increases the susceptibility for severe
infections. This may enhance the need for invasive ventilation
in ICUs upon acquiring COVID-19. The presence of other
co-morbidities especially type 2 diabetes and cardiovascular dis-
eases further aggravate the COVID-19 infection. Preventive
COVID-19 measures should also incorporate the encouragement
for healthy fresh food consumption and physical activity due to
their positive immune modulation. A number of COVID-19
response strategies recommendations have been put forward by
international organisations to ensure prevention, management
and safety of the population health. A prolonged quarantine
duration and administration of prophylaxis vitamin D may be
considered as part of the preventive strategies for individuals
with obesity.
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